inclusion criteria: i1) male or female patient aged 18 years or over, weighing \>50 kg and \<120 kg, at the time of signing the informed consent, i2) patient presenting in a specialized or an emergency unit i3) patient presenting signs of pneumonia evidenced by at least 1 of the following: auscultation, chest x-ray, ct scan or presenting covid-19 related symptoms having started less than 10 days prior to screening visit, including at least 2 of the following: fever, cough, sore throat or nasal discharge, dyspnea (shortness of breath), thoracic pain, headache or fatigue, myalgia, anosmia, dysgeusia, diarrhea, nausea i4) patient with spo2 \> 90% (at ambient air) i5) patient with a first positive sars-cov-2 test (rt-pcr, rt-qpcr or antigen test) in the last 10 days or at screening i6) women of childbearing potential (wocbp) must have a negative urine pregnancy test at screening and use a highly effective birth control until 90 days after the administration of study drug i7) non-vasectomized male patients having a female partner of childbearing potential must agree to use a highly effective method of contraception until 90 days after the administration of study drug, i8) patient capable of giving signed informed consent.

inclusion criteria: i1) male or female patient aged 18 years or over, weighing \>50 kg and \<120 kg, at the time of signing the informed consent, i2) patient presenting in a specialized or an emergency unit i3) patient presenting signs of pneumonia evidenced by at least 1 of the following: auscultation, chest x-ray, ct scan or presenting covid-19 related symptoms having started less than 10 days prior to screening visit, including at least 2 of the following: fever, cough, sore throat or nasal discharge, dyspnea (shortness of breath), thoracic pain, headache or fatigue, myalgia, anosmia, dysgeusia, diarrhea, nausea i4) patient with spo2 \> 90% (at ambient air) i5) patient with a first positive sars-cov-2 test (rt-pcr, rt-qpcr or antigen test) in the last 10 days or at screening i6) women of childbearing potential (wocbp) must have a negative urine pregnancy test at screening and use a highly effective birth control until 90 days after the administration of study drug i7) non-vasectomized male patients having a female partner of childbearing potential must agree to use a highly effective method of contraception until 90 days after the administration of study drug, i8) patient capable of giving signed informed consent.

inclusion criteria: i1) male or female patient aged 18 years or over, weighing >50 kg and <120 kg, at the time of signing the informed consent, i2) patient presenting in a specialized or an emergency unit i3) patient presenting signs of pneumonia evidenced by at least 1 of the following: auscultation, chest x-ray, ct scan or presenting covid-19 related symptoms having started less than 10 days prior to screening visit, including at least 2 of the following: fever, cough, sore throat or nasal discharge, dyspnea (shortness of breath), thoracic pain, headache or fatigue, myalgia, anosmia, dysgeusia, diarrhea, nausea i4) patient with spo2 > 90% (at ambient air) i5) patient with a first positive sars-cov-2 test (rt-pcr, rt-qpcr or antigen test) in the last 10 days or at screening i6) women of childbearing potential (wocbp) must have a negative urine pregnancy test at screening and use a highly effective birth control until 90 days after the administration of study drug i7) non-vasectomized male patients having a female partner of childbearing potential must agree to use a highly effective method of contraception until 90 days after the administration of study drug, i8) patient capable of giving signed informed consent.

inclusion criteria: i1) male or female patient aged 18 years or over, weighing >50 kg and <120 kg, at the time of signing the informed consent, i2) patient presenting in a specialized or an emergency unit i3) patient presenting signs of pneumonia evidenced by at least 1 of the following: auscultation, chest x-ray, ct scan or presenting covid-19 related symptoms having started less than 10 days prior to screening visit, including at least 2 of the following: fever, cough, sore throat or nasal discharge, dyspnea (shortness of breath), thoracic pain, headache or fatigue, myalgia, anosmia, dysgeusia, diarrhea, nausea i4) patient with spo2 > 90% (at ambient air) i5) patient with a first positive sars-cov-2 test (rt-pcr, rt-qpcr or antigen test) in the last 10 days or at screening i6) women of childbearing potential (wocbp) must have a negative urine pregnancy test at screening and use a highly effective birth control until 90 days after the administration of study drug i7) non-vasectomized male patients having a female partner of childbearing potential must agree to use a highly effective method of contraception until 90 days after the administration of study drug, i8) patient capable of giving signed informed consent.